Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort
Osteoporosis International · 2026
DOI: 10.1007/s00198-026-07862-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, 2026. Verfasst von Kousalya Prabahar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia. kgopal@ut.edu.sa. Hauptthemen laut MEDLINE: Denosumab, Hypocalcemia, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Denosumab-associated hypocalcemia is common in real-world settings. In this Saudi cohort, 21.1% developed hypocalcemia, with diuretic use and vitamin D deficiency as key predictors. Findings highlight that individualized risk assessment and monitoring may enhance the safety of osteoporosis treatment. BACKGROUND: Denosumab, a widely used antiresorptive agent for osteoporosis, has demonstrated significant benefits in reducing fracture risk. However, hypocalcemia is a recognized adverse effect, with real-world data suggesting higher incidence rates than those reported in clinical trials. This study explores the incidence, severity, and predictors of denosumab-associated hypocalcemia in a Saudi cohort. METHODS: A retrospective analysis was conducted at a tertiary care hospital, involving 303 Saudi adults with osteoporosis who received denosumab. The study evaluated changes in calcium levels, incidence of hypocalcemia, and potential risk factors, including vitamin D status, renal function, and medication use. Multivariate logistic regression identified predictors of hypocalcemia. RESULTS: Hypocalcemia occurred in 21.1% of patients, with 71.9% experiencing mild (grade 1) hypocalcemia. Most cases were asymptomatic (73.4%), with tingling and muscle aches reported in a minority of patients. Diuretic use emerged as a significant predictor (aOR 3.44, p = 0.008). Vitamin D deficiency was strongly associated with severe hypocalcemia (grade 3). Despite adherence to standard calcium and vitamin D supplementation, a substantial proportion of patients developed hypocalcemia, underscoring the need for individualized monitoring. CONCLUSION: Hypocalcemia following denosumab is common in real-world practice, particularly in patients on diuretics or with low vitamin D levels. Clinicians should consider comprehensive pre-treatment risk assessment and tailored monitoring strategies to mitigate adverse outcomes in osteoporosis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia. kgopal@ut.edu.sa.
- Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.
Zitieren
APA
Prabahar, K., Alharthi, N. M., & AlKenani, R. (2026). Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort. Osteoporosis International. https://doi.org/10.1007/s00198-026-07862-5
Vancouver
Prabahar K, Alharthi NM, AlKenani R. Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort. Osteoporosis International. 2026. doi:10.1007/s00198-026-07862-5
BibTeX
@article{Prabahar2026,
author = {Prabahar, Kousalya and Alharthi, Nouf M and AlKenani, Rola},
title = {Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort},
journal = {Osteoporosis International},
year = {2026},
doi = {10.1007/s00198-026-07862-5}
}
EUVIMED